10-Q: Venus Concept Reports Q2 2024 Results Amid Strategic Review

Venus Concept's Q2 2024 results show a decrease in revenue and a net loss, while the company continues its strategic review process.

Summary

• Venus Concept reported a revenue of $16.6 million for the second quarter of 2024, a decrease from $20.1 million in the same period last year.
• The company's net loss attributable to stockholders was $19.9 million for the quarter, compared to a loss of $7.4 million in Q2 2023.
• The company's accumulated deficit reached $291.6 million as of June 30, 2024.
• The company is undergoing a strategic review to maximize shareholder value, which may include financings, mergers, or asset sales.
• The company's cash and cash equivalents were $5.7 million as of June 30, 2024.
• The company's total debt obligations were approximately $46.0 million as of June 30, 2024.
• The company's adjusted EBITDA loss was $4.1 million for the three months ended June 30, 2024.
• The company sold 222 systems in Q2 2024, compared to 332 systems in Q2 2023.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including decreased revenue, increased losses, and high debt levels. While the company is taking steps to address these issues, the overall sentiment is negative due to the company's financial performance and the risks it faces.

Positives

• Cash used in operations in the first half of 2024 was 47% less than the first half of 2023.
• The company is focusing on traditional cash sales over internal lease programs to improve cash generation.
• The company's allowance for expected credit losses decreased to $4.2 million as of June 30, 2024, from $7.4 million as of December 31, 2023.

Negatives

• The company experienced a significant decrease in revenue and an increase in net loss compared to the same period last year.
• The company's accumulated deficit continues to grow.
• The company is facing challenges due to tighter credit markets and higher interest rates.
• The company is experiencing supply chain challenges due to geopolitical disruption in the middle east.
• The company is experiencing inflationary pressures throughout its supply chain.

Risks

• The company's ability to continue as a going concern is dependent on achieving profitability or obtaining additional financing.
• The company is exposed to credit risk from customers under its internal lease programs.
• The company's operations are subject to risks related to political, economic, and military conditions in Israel.
• The company may not be able to maintain its listing on the Nasdaq Capital Market.
• The company is subject to various covenants in its debt agreements that could restrict its operations.
• The company is exposed to foreign exchange risk with respect to revenues generated outside of the United States.

Future Outlook

The company expects to continue to incur substantial operating losses and negative cash flows from operations until it generates sufficient revenue to support its cost structure. The company plans to fund its operations with cash on hand, borrowings, and issuances of capital stock. The company anticipates some supply challenges in the second half of 2024 due to geopolitical disruption in the middle east impacting shipping lanes, deliveries of materials and component parts, impacting production lead times that may impact the company's ability to manufacture the number of systems required to meet customer demand.

Management Comments

• The company is focused on adapting to the challenges presented by the current macro-economic environment.
• The company is focused on quality of revenue and despite the revenue decline, its cash used in operations was $3.8 million lower, or 47%, than the same period in 2023.
• The company remains fully focused on its revised credit screening practices and thereby reducing bad debt expenses.

Industry Context

The medical aesthetic industry is facing challenges due to economic uncertainty, including high inflation and interest rates, which are impacting customer spending and access to financing. Venus Concept is adapting to these challenges by focusing on cash sales, reducing operating costs, and exploring strategic alternatives.

Comparison to Industry Standards

• The decrease in revenue and increase in net loss are concerning and may indicate underperformance compared to industry peers.
• The company's focus on cash sales and cost reduction is a common strategy in the current economic environment, but its effectiveness remains to be seen.
• The company's debt levels are high, which could limit its financial flexibility compared to competitors with stronger balance sheets.
• The company's strategic review process is a sign that it is exploring options to improve its financial position, which may be necessary given its current performance.

Related Party Transactions

• The company had distribution agreements with Technicalbiomed Co., Ltd. (TBC) and Aexel Biomed Pte Ltd. (Aexel Biomed), both of which are related parties through former senior officers. TBC and Aexel Biomed ceased being related parties as of June 2023.

Stakeholder Impact

• Shareholders are impacted by the company's decreased revenue, increased losses, and high debt levels.
• Employees may be impacted by potential cost-cutting measures or restructuring.
• Customers may be impacted by potential supply chain disruptions or changes in financing options.
• Suppliers may be impacted by potential changes in the company's purchasing patterns or financial stability.
• Creditors are impacted by the company's high debt levels and potential for default.

Next Steps

• The company will continue to evaluate strategic alternatives to maximize shareholder value.
• The company will continue to focus on cash sales and cost reduction.
• The company will continue to monitor and mitigate supply chain challenges.
• The company will continue to monitor and mitigate the impact of the conflict in Israel on its operations.

Key Dates

Keywords

Venus Concept, financial results, Q2 2024, strategic review, medical technology, aesthetic devices, debt, revenue, net loss, EBITDA, financing, Nasdaq